{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:03:47Z","timestamp":1777356227551,"version":"3.51.4"},"reference-count":6,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:p>Ankylosing spondylitis (AS) is a disabling disease affecting the enthesis and joints of the spine and peripheral sites. Tumour necrosis factor \u03b1 (TNF-\u03b1) is a proinflammatory mediator which plays a significant role in the pathogenesis of AS. Infliximab (a chimeric monoclonal antibody which blocks the activity of TNF-\u03b1) is one of the most effective therapies of AS thus far. Vitiligo is a depigmenting disorder of the skin of unknown aetiology affecting 0.5\u20131% of the population. Here we describe the effect of infliximab on vitiligo in a patient with AS.<\/jats:p>","DOI":"10.1159\/000112932","type":"journal-article","created":{"date-parts":[[2008,1,9]],"date-time":"2008-01-09T10:19:35Z","timestamp":1199873975000},"page":"234-235","source":"Crossref","is-referenced-by-count":34,"title":["Vitiligo Improvement in a Patient with Ankylosing Spondylitis Treated with Infliximab"],"prefix":"10.1159","volume":"216","author":[{"given":"J.-Abraham","family":"Sim\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Burgos-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165%2F00003495-200464010-00006"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000102044"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1432-1327.1998.2550139.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2F1523-1747.ep12460991"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaut.2005.10.001"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1600-0749.2002.1o049.x"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/112932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/112932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:33:51Z","timestamp":1745462031000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000112932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":6,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000112932","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}